Concord Biotech has issued a certificate confirming compliance with SEBI regulations for the quarter ended September 30, 2025. The certificate, dated October 6, 2025, confirms the dematerialization of securities and proper handling of related processes through MUFG Intime India Private Limited, the Registrar and Share Transfer Agent.
Compliance Confirmation
Concord Biotech has confirmed adherence to regulatory requirements regarding the handling of securities during the dematerialization process for Q2 FY26, which ended on September 30, 2025.
Details of Certification
A certificate dated October 6, 2025, issued by MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, affirms that securities received for dematerialization have been duly processed. This includes confirmation to depositories and ensuring listed securities are accurately reflected on stock exchanges.
Key Aspects of Compliance
The company confirms that all security certificates received for dematerialization have been appropriately managed, including mutilation and cancellation after verification by the depository participant. The register of members has been updated to reflect the depositories as registered owners within the stipulated timelines.
Source: BSE
